Targeted therapies in gastric cancer and future perspectives

Table 2 Finished Phase II studies

Target	Agents	Name of Trial and Setting	Phase	Number of patients	PFS (mo)	OS (mo)	Results
HER-2	Lapatinib	S0413, First line	II	47	1.9	4.8	Positive
HER-2	Lapatinib plus ECF or ECX vs placebo plus ECF or ECX	EORTC 40071, First line	II	28	7.1 vs 5.9	13.8 vs 10.1	Negative1
HER-2	MK-2206 (AKT inhibitor)	S1005, Second line	II	70	1.8	5.1	Negative
Pan-HER	Saracatinib (Src inhibitor)	NN, ≥ Second line	II	21	1.8	7.8	Negative
Pan-HER	Dacomitinib	NN, ≥ Second line	II	27	2.1	7.1	Positive
EGFR	Cetuximab plus mFOLFOX6	NN, First line	II	40	5.5	9.9	Positive
EGFR	Cetuximab plus FOLFIRI	NN, First line	II	49	9.0	16.5	Positive
EGFR	Panitumumab with dose dense DCF	NN, First line	II	52	4.8	9.4	Positive
VEGF	Bevacizumab plus irinotecan and cisplatin	NN, First line	II	47	8.3	12.3	Positive
VEGF	Bevacizumab plus docetaxel/oxaliplatin	NN, First line	II	38	6.6	11.1	Positive
m-TOR	Everolimus 10 mg	NN, ≥ Second line	II	53	2.7	10.1	Positive

¹Early terminated. VEGF: Vascular endothelial growth factor; m-TOR: Mammalian target of rapamycin; NN: No specific study name was defined.